The Nano-Bio Manufacturing Consortium (NBMC), an industry-academia partnership with the United States Air Force Research Laboratory (AFRL), has chosen a project proposed by the Arizona Center for Integrative Medicine (AzCIM) at the University of Arizona College of Medicine – Tucson, to receive research funding. The AzCIM project’s goal is to assess different sweat collection methods and devices for their ability to collect different volumes of sweat under a variety of human-body conditions, the results of which will help determine the best method for integrating into a wearable sensor system. Funding for the one year program will total $200,000.
Nano-Bio Manufacturing Consortium Selects Project Proposed by Arizona Center for Integrative Medicine to Optimize Human Performance Monitoring Techniques
Cypher Genomics, Inc., the genome informatics company, recently announced the identification of de novo KCNB1 missense mutations as a novel genetic cause of severe epileptic encephalopathy. Cypher’s co-founder and Chief Scientific Officer Ali Torkamani, Ph.D. reviewed the data today at a platform presentation at the ASHG 2014 meeting being held October 18 to 22 in San Diego. This study highlights how Cypher’s Mantis(TM )technology, which incorporates commercial access to the Scripps Wellderly Cohort as a genome reference population, can rapidly and accurately identify novel causes of rare diseases.
BioNano Genomics recently announced achievement of a major milestone for the Irys system: the ability to collect human data at 30X depth, sufficient for a genome map, in 24 hours on a single chip. This new capability was established and demonstrated for the IrysChipTM V2, the high-throughput chip for the IrysTM System and will be rolled out to BioNano’s collaborators and customers over the next two months. BioNano will be showcasing this advancement at the American Society for Human Genetics (ASHG) 2014 Meeting taking place October 18-22 in San Diego. The one human : one chip : one day will provide a more rapid, accurate and comprehensive way of identifying structural variation to drive genomics discoveries. BioNano also announced major software updates to IrysViewTM and IrysSolveTM, to improve visualization and analysis.
Not since the commercialization of polymerase chain reaction tests has molecular diagnostics been presented with such a promising technology as next-generation sequencing (NGS), according to healthcare market research firm Kalorama Information. NGS’s blue-chip status was discussed in the recently published The Worldwide Market for In Vitro Diagnostics, 9th Edition.
A new blood test reliably predicts whether a person is likely to develop Alzheimer’s Disease (AD) up to 10 years before the disease is diagnosed, according to a multi-site study recently published in the Alzheimer’s Association journal Alzheimer’s & Dementia.